logo-loader
viewMedexus Pharmaceuticals Inc

Full interview: Medexus Pharmaceuticals reveals 3Q highlights and potential acquisition activity

Medexus Pharmaceuticals Inc (CVE:KMDP) (OCTMKTS:PDDPF) CEO Ken d’Entremont tells Proactive the pharmaceutical company is showing strong organic growth from its three main revenue drivers, including Resuvo, Metoject, and Rupall, bringing revenue of C$16.2 million for its Q3, compared to revenue of C$14.4 million for the same period a year earlier.

d’Entremont says meanwhile, the company's expenses are growing - as strong evidence it has been 'very busy' on the business development front, expecting to potentially close an acquisition in the near future.

Quick facts: Medexus Pharmaceuticals Inc

Price: 2.5 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $35.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Medexus Pharmaceuticals ensuring its prescription drug...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCMKTS:PDDPF) CEO Ken d’Entremont tells Proactive its business remains strong in the face of the coronavirus outbreak. d’Entremont says the pharmaceutical company is ensuring its supply chain remains 'solid' and is sitting on 3-6 months of prescription...

3 days, 9 hours ago

2 min read